Bavarian Nordic data shows booster shot protects against Omicron
A phase II study has demonstrated that the biotech firm’s Covid-19 vaccine candidate still provides a high level of protection against Omicron, although antibody levels were lower compared to all previously reported variants.
by mikkel aabenhus hemmingsen, translated by daniel pedersen
Danish biotech firm Bavarian Nordic has demonstrated in a phase II trial that vaccine candidate ABNCoV2 provides protection against the currently dominant Covid-19 variant, Omicron, the company announced in a Thursday press release.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
